Eptacog alfa - Novo Nordisk
Alternative Names: Activated recombinant human factor VII; Factor VIIa; NiaStase; NN 007; NovoSeven; NovoSeven RT; NovoSeven RT with MixProT; NovoSeven with pre-filled syringe; Novostase; Recombinant factor VIIa; rFVIIaLatest Information Update: 24 Nov 2025
At a glance
- Originator ZymoGenetics
- Developer Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIIa stimulants; Factor X stimulants
-
Orphan Drug Status
Yes - Haemophilia; Thrombasthenia; Haemorrhage
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Factor VII deficiency; Haemophilia; Postpartum haemorrhage; Thrombasthenia
- Phase III Haemorrhage
Most Recent Events
- 24 Nov 2025 Launched for Postpartum haemorrhage in Austria (IV)
- 24 Nov 2025 Launched for Postpartum haemorrhage in Belgium (IV)
- 24 Nov 2025 Launched for Postpartum haemorrhage in Croatia (IV)